EICHOR
● Recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Condition: Glioblastoma · Sponsor: NovoCure GmbH
About this study
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
This description comes directly from the study's public registry record.
Talk to the study team
Uz Stammberger · 1-877-678-8611 · clinicaltrials@novocure.com
Always discuss trial participation with your own doctor first.
Locations (102)
| Mayo Clinic Hospital | Phoenix, Arizona, United States | Active Not Recruiting |
| University of Southern California | Los Angeles, California, United States | Active Not Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Active Not Recruiting |
| Stanford Cancer Institute | Palo Alto, California, United States | Active Not Recruiting |
| University of California | San Francisco, California, United States | Active Not Recruiting |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Active Not Recruiting |
| UF Health Neuromedicine | Gainesville, Florida, United States | Active Not Recruiting |
| Mayo Clinic - Florida | Jacksonville, Florida, United States | Active Not Recruiting |
| Miami Cancer Institute | Miami, Florida, United States | Active Not Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Active Not Recruiting |
| Northwestern Memorial Hospital | Chicago, Illinois, United States | Active Not Recruiting |
| University of Kentucky Medical Center | Lexington, Kentucky, United States | Active Not Recruiting |
+ 90 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06556563